Gilead Sciences
Gilead Sciences develops and sells innovative medicines for HIV, viral hepatitis, cancer and inflammatory diseases. Its virology business, particularly HIV treatments and prevention medicines, is a major part of the company's pharmaceutical business, while its oncology business focuses on cancer therapies.
吉利德科学是一家生物制药公司,主要研发和销售用于治疗 HIV(艾滋病病毒)、病毒性肝炎、癌症及炎症性疾病的创新药物。其中,抗病毒业务,尤其是 HIV 治疗与预防药物,是公司的核心业务之一,而肿瘤业务则专注于癌症治疗药物的研发与销售。
The forecast figures are tipranks’s, read on 2026-11-16 and linked below.
SmartChecker Gilead Sciences Forecast
The forecast in short
tipranks records 23 analyst ratings on Gilead Sciences and summarises them as “Strong Buy”. Their average 12-month price target is USD 173.76 (3.38% Upside). Its tipranks score is 10 out of 10 — Outperform. These are tipranks’s figures as SmartChecker read them on 2026-11-16, not SmartChecker’s own view, and nothing here is advice to buy or sell.
Market cap
USD 208.48 B
≈ RM 852.19 B
Share price
USD 168.08
≈ RM 687.08
#83World ranking
tipranks score
Outperform
Analyst ratings
Strong Buy
- Buy18 78%
- Hold5 22%
- Sell0 0%
tipranks’s own summary of the 23 ratings above.
12 months price forecast
USD 173.76 3.38% Upside
As tipranks publishes it. SmartChecker has not recalculated any of it.
Analyst profiles. Who made each call, and when.
| Analyst | From | Position | Target price | Dated |
|---|---|---|---|---|
| Jasper Hellweg | Argus Research | Buy | USD 190 | 2026-11-11 |
| Louise Chen | Scotiabank | Buy | USD 200 | 2026-11-10 |
| Michael Okunewitch | Maxim Group | Buy | N/A | 2026-11-05 |
| Brian Abrahams | RBC Capital | Hold | USD 131 | 2026-11-05 |
| Geoff Meacham | Citi | Buy | USD 188 | 2026-11-04 |
| Evan Seigerman | BMO Capital | Buy | USD 184 | 2026-11-02 |
| Daina Graybosch | Leerink Partners | Hold | USD 145 | 2026-11-02 |
| Mohit Bansal | Wells Fargo | Buy | USD 190 | 2026-10-30 |
| Joseph Stringer | Needham | Buy | USD 200 | 2026-10-30 |
| Michael Yee | UBS | Buy | USD 195 | 2026-10-30 |
| Terence Flynn | Morgan Stanley | Buy | USD 183 | 2026-10-30 |
| Tyler Van Buren | TD Cowen | Buy | USD 175 | 2026-10-30 |
| Chris Schott | J.P. Morgan | Buy | USD 190 | 2026-10-30 |
| Gregory Renza | Truist Financial | Buy | USD 181 | 2026-10-30 |
| Umer Raffat | Evercore ISI | Buy | N/A | 2026-10-30 |
| Carter Gould | Cantor Fitzgerald | Buy | USD 175 | 2026-10-29 |
| Salveen Richter | Goldman Sachs | Hold | USD 155 | 2026-10-29 |
| Emily Field | Barclays | Hold | USD 145 | 2026-10-28 |
| Brian Skorney | Robert W. Baird | Hold | USD 145 | 2026-10-27 |
| Courtney Breen | Bernstein | Buy | USD 160 | 2026-10-25 |
| Tazeen Ahmad | Bank of America Securities | Buy | USD 172 | 2026-10-20 |
| Morten Herholdt | HSBC | Buy | USD 175 | 2026-09-10 |
| Salim Syed | Mizuho Securities | Buy | USD 170 | 2026-08-31 |
| Akash Tewari | Jefferies | Buy | USD 180 | 2026-05-22 |
Show moreShow less
Investment Strengths
Strong cash generation强劲的现金创造能力
Exceptionally strong operating and free cash flow provides financial resilience even when reported earnings are weak. This supports continued investment in research and development, funding for launches, debt servicing, and shareholder returns without relying solely on external financing.极为强劲的经营现金流和自由现金流,即使在财报盈利表现疲弱的情况下,仍能为公司提供稳健的财务保障。这使公司能够持续投入研发、支持新产品上市、偿还债务及回馈股东,而无需过度依赖外部融资。
HIV franchise momentumHIV 业务特许经营优势持续增强
The HIV franchise combines recurring chronic-treatment demand with strong product adoption and market leadership. Growth in Biktarvy, prevention products, and newer options such as Yeztugo gives Gilead a durable commercial base and supports continued cash generation.HIV 业务结合了长期稳定的慢性治疗需求、强劲的产品市场接受度及领先的市场地位。其中,Biktarvy、预防类产品,以及 Yeztugo 等新一代治疗与预防选择的增长,为 Gilead 建立了稳固且可持续的商业基础,并支持公司持续创造现金流。
Pipeline diversification研发管线多元化
A broad pipeline across several therapeutic areas can reduce dependence on any single product or franchise over time. Continued development in oncology and inflammation, alongside multiple long-acting HIV programs, improves the company’s prospects for renewing growth.公司在多个治疗领域拥有广泛的研发管线,长远来看有助于降低对单一产品或业务板块的依赖。除了持续推进肿瘤学和炎症领域的研发项目外,公司也在开发多项长效 HIV 治疗方案,进一步提升未来推出新产品及实现新一轮增长的潜力。
People also ask
What is the 12-month price target for Gilead Sciences (GILD)?
tipranks publishes an average 12-month price target of USD 173.76 (3.38% Upside), as SmartChecker read it on 2026-11-16. The highest target is USD 200 and the lowest is USD 131. A price target is an analyst’s estimate of where a share might trade, not a promise, and SmartChecker gives no investment advice.
See tipranks’s own page ↗How many analysts cover Gilead Sciences (GILD)?
tipranks records 23 analyst ratings: 18 buy, 5 hold and 0 sell, which it summarises as “Strong Buy”, as SmartChecker read it on 2026-11-16.
See tipranks’s own page ↗What is the tipranks score for Gilead Sciences (GILD)?
tipranks scores it 10 out of 10 and calls that “Outperform”, as SmartChecker read it on 2026-11-16. The score is tipranks’s, not SmartChecker’s, and SmartChecker does not rate listed shares.
See tipranks’s own page ↗Is this SmartChecker’s own forecast for Gilead Sciences?
No. Every figure on this page is published by tipranks, copied on 2026-11-16 with a link to the original, and not recalculated. SmartChecker assesses financial companies in Malaysia against the public registers; it makes no forecast of its own and holds no licence to advise on securities.
See tipranks’s own page ↗Member reviews. Members’ own ratings and words, not SmartChecker’s rating.
These ratings and words are written by SmartChecker members and published immediately without administrator approval. SmartChecker does not rate listed companies: a rating here belongs to whoever wrote it, it counts towards no score of ours, and nothing in it is advice.
Disclaimer
SmartChecker provides informational and financial market news only and does not provide investment, financial or legal advice.
